Bharat Parenterals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bharat Parenterals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 58% in 3 years, but profit fell: ₹20 less profit per ₹100 of extra sales. Lower than 95% of Healthcare companies in India.
- Shareholder Slice Ratio: Share count rose 19% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 91% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years its own operating cash paid for 4% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares. Lower than 90% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
0.0×Over the last 3 years its own operating cash paid for 4% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 90% of Healthcare companies in India.
Cash Locked Ratio
₹42For every ₹100 of sales, ₹42 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹36 tied up three years earlier.
More money tied up than 81% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
−₹20Sales grew 58% in 3 years, but profit fell: ₹20 less profit per ₹100 of extra sales.
Lower than 95% of Healthcare companies in India.
Asset Productivity Ratio
+58% / +75%In 3 years sales changed by +58% while total assets changed by +75%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
1.6×Debt due within a year is covered 1.6 times by its yearly operating cash.
Higher than 55% of Healthcare companies in India.
Cash Cushion Ratio
−11%Debt, after subtracting cash, equals 11% of its market value (net debt).
Lower than 81% of Healthcare companies in India.
Tangible Assets Ratio
91%Of every ₹100 the company owns, ₹91 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 66% of Healthcare companies in India.
Tangible Net Worth Ratio
83%Of every ₹100 of net worth, ₹83 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 70% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Bharat Parenterals Limited made a loss over the last year. Bharat Parenterals Limited owes ₹0.49 for every ₹1 it owns. Bharat Parenterals Limited made a loss in each of the last two years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
LossBharat Parenterals Limited made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.80The share price is 3.80 times Bharat Parenterals Limited's book value per share, lower than 62% of Healthcare companies in India.
Market cap
₹1,224 CrThe total market value of all of Bharat Parenterals Limited's shares at today's price (share price × number of shares), smaller than 77% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹322 CrWhat Bharat Parenterals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹467.55Net worth divided by the number of shares. The share price of ₹1,776 is 3.8 times this, which is the P/B above.
Return on equity (ROE)
-4.8%Bharat Parenterals Limited lost 4.8% of its shareholders' money over the last year, lower than 97% of Healthcare companies in India.
Owes vs Owns
0.49×Bharat Parenterals Limited owes ₹0.49 for every ₹1 it owns (low), higher than 81% of Healthcare companies in India.
Dividend yield
0.05%Bharat Parenterals Limited pays 0.05% of its share price as dividends a year, lower than 96% of dividend-paying Healthcare companies in India.
Revenue growth
+2%Revenue rose 2% in the year to Mar 2026, and grew 16% a year on average over 3 years.
Profit growth
LossBharat Parenterals Limited made a loss in each of the last two years.
Profit margin
-2.4%Bharat Parenterals Limited lost ₹2 for every ₹100 of revenue.
Interest cover
Not coveredBharat Parenterals Limited's operating profit did not cover its interest costs in the year to Mar 2026.
Cash vs debt
Net debtBharat Parenterals Limited had ₹139 Cr more debt than cash (net debt) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bharat Parenterals Limited: ₹1,224 Cr ÷ ₹322 Cr (31 Mar 2026) = 3.8.
What is Bharat Parenterals Limited's return on equity?
Bharat Parenterals Limited lost 4.8% of its shareholders' money over the last year, lower than 97% of Healthcare companies in India.
How much does Bharat Parenterals Limited owe compared with what it owns?
Bharat Parenterals Limited owes ₹0.49 for every ₹1 it owns (low), higher than 81% of Healthcare companies in India.
Does Bharat Parenterals Limited pay a dividend?
Yes. Bharat Parenterals Limited pays 0.05% of its share price as dividends a year, lower than 96% of dividend-paying Healthcare companies in India.
Is Bharat Parenterals Limited's revenue growing?
Revenue rose 2% in the year to Mar 2026, and grew 16% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.